Beijing Biostar Pharmaceuticals Co., Ltd. Class H

As of June 30, 2026, Beijing Biostar Pharmaceuticals Co., Ltd. Class H carries a market capitalization of 1.39B, placing it among publicly traded companies globally. Its enterprise value stands at 843.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Beijing Biostar Pharmaceuticals Co., Ltd. Class H's next confirmed earnings release is scheduled for July 5, 2027.

As of June 30, 2026, Beijing Biostar Pharmaceuticals Co., Ltd. Class H has 364.59M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Beijing Biostar Pharmaceuticals Co., Ltd. Class H maintains a current ratio of 8.77, meaning it holds 8.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Beijing Biostar Pharmaceuticals Co., Ltd. Class H's stock has declined approximately 29.48% over the past 52 weeks. The 50-day moving average sits at 3.87, while the 200-day moving average is 3.74.

As of June 30, 2026, Beijing Biostar Pharmaceuticals Co., Ltd. Class H holds 543.69M in cash and equivalents against 1.61M in total debt, resulting in a net debt position of -543.69M. Total book value stands at 739.55M, with working capital of 562.88M providing operational flexibility.